Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...

Chris Gibson, Recursion’s head, cited the role small business grants played in helping Recursion grow its business.

NVIDIA's continued investment in Recursion Pharmaceuticals strengthens the view that Recursion is a favored investment within ...

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...

That was the case for Recursion Pharmaceuticals, a now publicly traded company that applies artificial intelligence to drug discovery and development. With layoffs at the NIH underway and its ...